Genetic variants in GCKR, GIPR, ADCY5 and VPS13C and the risk of severe sulfonylurea-induced hypoglycaemia in patients with type 2 diabetes

Abstract

Objective:

Severe hypoglycaemia (SH) induced by sulfonylureas is a life-threatening condition. We hypothesized that recently identified polymorphisms associated with insulin secretion in GCKR, GIPR, ADCY5 and VPS13C genes affect the response to sulfonylureas in patients with type 2 diabetes (T2D) and so, result in reduced risk for SH.

Research design and methods:

We assessed the prevalence of GCKR, GIPR, ADCY5 and VPS13C polymorphisms in a case-control study including 111 patients with SH and 100 patients with T2D but without a history of SH. All patients were treated with the sulfonylurea drugs glimepiride, glibenclamide or gliquidon. SH was defined as a symptomatic event with blood glucose of <50 mg/dl requiring treatment with intravenous glucose.

Results:

In logistic regression analyses, a low HbA_1c and a higher sulfonylurea dose appeared to be the only predictors of SH (P=0.001 and P=0.04, respectively). There was no significant difference in the genotype distribution between the control group and the cases with SH for any of the investigated polymorphisms (OR and 95% confidence intervals – 0.90 (0.59–1.38) for GCKR; 1.11 (0.67–1.85) for GIPR; 0.75 (0.48–1.17) for ADCY5; 1.43 (0.95–2.15) for VPS13C; all P-values >0.05). Also, there was no significant effect of the examined genetic variants on HbA1c levels (all P-values >0.05 adjusted for age, sex, BMI, diabetes duration, sulfonylurea dose).

Conclusions:

We found no detectable effect (with an OR >2.1) of the variants in GCKR, GIPR, ADCY5 and VPS13C on the response to sulfonylurea treatment, indicating that these variants are not significantly contributing to the risk of SH in patients with T2D.

Key words

sulfonylurea - severe hypoglycaemia - polymorphisms - type 2 diabetes

• References

• 1 Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diab 2003; 111: 405-414
• 2 Holstein A, Hahn M, Stumvoll M et al. The E23K Variant of KCNJ11 and the Risk for Severe Sulfonylurea-induced Hypoglycemia in Patients with Type 2 Diabetes. Horm Metab Res 2009; 41: 387-390
• 3 Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-1418
• 4 Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42: 105-116
• 5 Saxena R, Hivert MF, Langenberg C et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42: 142-148
• 6 Holstein JD, Kovacs P, Patzer O et al. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics 2012; 13: 5-7
• 7 Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Statistics in Medicine 2002; 21: 35-50
• 8 Holstein A, Hahn M, Körner A et al. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet 2011; 12: 30
• 9 Pearson ER, Donnelly LA, Kimber C et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas – A GoDARTs study. Diabetes 2007; 56: 2178-2182
• 10 Sesti G, Laratta E, Cardellini M et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 2334-2339
• 11 Lang VY, Fatehi M, Light PE. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenet Genomics 2012; 22: 206-214
• 12 Ingelsson E, Langenberg C, Hivert MF et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans. Diabetes 2010; 59: 1266-1275
• 13 Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206
• 14 Beer NL, Tribble ND, McCulloch LJ et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009; 8: 4081-4088
• 15 Van Schaftingen E, Detheux M, Veiga da Cunha M. Short-term control of glucokinase activity: role of regulatory protein. FASEB J 1994; 8: 414-419